Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on August 4, 2025
Castle Biosciences Reports Second Quarter 2025 Results
Delivered Q2 2025 revenue of $86 million Q2 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 33% over Q2 2024 Raising full-year 2025 revenue guidance range to $310-320 million from $287-297 million …
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases …
Tactile Systems Technology, Inc. Reports Second Quarter 2025 Financial Results
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the …
OrthoPediatrics Corp. to Participate in the 45th Canaccord Genuity Annual Growth Conference
WARSAW, Ind., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President …
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, …
iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference
NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live …
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …
FibroGen to Report Second Quarter 2025 Financial Results
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern …
Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with …
Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated net sales revenue of $25.0 million …
Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug …
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by …
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia
First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA’s Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage …
Dunham House to Partner with CrossMed Healthcare Staffing
OMAHA, Neb., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dunham House, a first-of-its-kind, transformational initiative for combat-wounded veterans in need of long-term residential-centered care for their wounds, will partner with Omaha-based CrossMed Healthcare …
ACGME International Expands to Indonesia, Accredits New Programs in Japan and Lebanon
Chicago, Illinois, US, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ACGME International (ACGME-I) is proud to announce the beginning of its accreditation activities in Indonesia as six institutions have achieved Initial Accreditation. The newly accredited Sponsoring …
Media advisory: Shriners Hospitals for Children Canada Invites Media to its Annual Golf Tournament
MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- What: Shriners Hospitals for Children Canada invites members of the media to attend a special photo and interview opportunity during its Annual Golf Tournament at Summerlea Golf …
Avis aux médias: L’Hôpital Shriners pour enfants Canada invite les médias à son tournoi de golf annuel
Quoi : L’Hôpital Shriners pour enfants Canada convie les représentants des médias à une occasion spéciale de photos et d’entrevues dans le cadre de son tournoi de golf annuel, qui se tiendra au club Summerlea Golf …
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled arm. A parallel study presented to …
Healthcare Workforce Management Market Surges Amid Drive for Operational Efficiency and Cost Reduction
Boston, Aug. 04, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Healthcare Workforce Management System Market” is expected to grow from $1.9 billion in 2024 to $3.1 billion by the end of 2029, at a compound annual …
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the …